Phase 1 Relapsed Refractory Multiple Myeloma (RRMM) Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled2 locationsNCT07455851
Recruiting
Phase 1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital25 enrolled3 locationsNCT07032714
Recruiting
Phase 1Phase 2
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH75 enrolled7 locationsNCT06645678